Advertisement

Topics

Grünenthal Company Profile

21:37 EDT 31st May 2016 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [25 Associated News Articles listed on BioPortfolio]

Germany’s Grünenthal to acquire Almirall’s Mexican operations

Grünenthal Group has entered into a definitive agreement with Almirall under which Grünenthal will…

Grünenthal to capitalize on Axxam’s drug discovery platform

Family-owned German drugmaker Grünenthal has entered into a collaboration with Italian biotech company…

Grünenthal selects Patheon to develop drugs using INTAC abuse deterrent formulations technology

Patheon has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred de...

Grünenthal and Akashi ink deal on HT-100 Duchenne muscular dystrophy candidate

Grünenthal on Friday announced the joint global drug development program with USA-based Akashi Therapeutics…

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to enter into the gastroenterology segment and ...

Grünenthal Group to acquire Almirall’s Mexico unit for about 50 million euro

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about 50 million euros to enter into the gastroenterology segment and exp...

Grünenthal formulates deal with Patheon for anti-abuse technology

Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.

Grünenthal and Akashi to develop HT-100 to treat DMD patients

German pharmaceutical firm Grünenthal has entered a joint global drug development programme to develop US-based Akashi Therapeutics’ orally available small molecule drug candidate, HT-100, to treat...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record